Copyright
©The Author(s) 2024.
World J Hepatol. Apr 27, 2024; 16(4): 566-600
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.566
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.566
NPs | Size | Tested model | Dose & route of administration | Effects & mechanism | Ref. |
Cd/Se/Te QD705 | 12.3 ± 5.2 nm (TEM) | ICR mice | 100 μL of 40 and 160 pmol (IV) sacrificed at 12 and 16 wk | ALT, AST (increased); GPx, HO-1, 8-oxo-dG (increased); Cu/Zn/Se (increased); SOD activity (decreased); GSH/GSSG; Unbalanced antioxidation systems; Trace metals, trace metal transporters; TNFα, IL-6 (increased) | [167] |
Oxidative stress and inflammation | |||||
CdSe QD | 4 nm (TEM) | Kunming mice Hepa 1–6 cells | 200 nMCdCl2, 20 nM & 200 nM QDs (acute) for 48 h (IP); 20 nMCdCl2, 5 nM & 10 nM QDs for 6 wk (chronic) (IP); 20 nM CdCl2, 5 nM, 10 nM and 20 nM QDs for 24 & 48 h | ROS, MDA (increased); GSH-Px (decreased); Enlarged central vein, disordered hepatic cords; Reduced cell size, condensation; Round and condensed macrophage | [166] |
Oxidative stress | |||||
Mn-doped ZnS QDs | 3.8 ± 0.1 nm (TEM) | Kunming mice | 1 & 5 mg/kg (QDs); 5 mg/kg (QDs PEG) (IV) for 7 da sacrificed on 8th & 28th day | QDs accumulated in mitichondia, lysosome, lipid droplets; No hepatic damage | [169] |
CdTe QDs | 2.2 nm (TEM) | AML 12; ICR mice | 27.66, 41.49, 53.94, 70.12, 91.16 & 118.50 μg/mL for 24 & 48 h. 4.125, 8.25 and 16.5 mg/kg body weight (IV) once a week for 4 wk | LPO, MDA, SOD, CAT, P53, Bcl-2, Nrf2, HO-1 (increased); Bax (decreased); ATP concentration (decreased); Nrf2 signaling pathway activation | [170] |
Oxidative stress, apoptosis | |||||
CdTe QDs | 7.3 ± 1.2 nm (TEM) | HepG2 cell | 10 μg/mL containing 1 μg/mL of cadmium for 24 h | MMP disruption, mitochondrial swelling, increased intracellular ca2+ levels, impaired cellular respiration & decreased ATP synthesis; PGC-1α (increased) | [171] |
Mitochondrial toxicity & dysfunction | |||||
CdTe QDs | 15.25 ± 0.34 nm (TEM) | BALB/c mice | 0.4, 2, 5, 6, 7, and 10 mg/kg b.w (Iv) for 24 h; 5 mg/kg bw (Iv) 2 h, 24 h, 3 d, and 1 wk | Enlarged mitochondria with increment in number; Affects ETC complex & ATP synthesis energy metabolism impairment | [172] |
Mitochondrial dysfunction | |||||
CdSe/Zn-QD | 7.1 nm (TEM) | L02 cells; C57BL/6 mice; NLRP3 knockout mice | 5, 10, 20, 40, 80 nM, 24 and 48 h; 10 nmol/kg (IV) results at 2 wk | Dose-dependent decrease in cell viability pyroptosis; Caspase-1 activity(increased); NLRP3 inflammasome activation; mt ROS production (increased); Cytoplasmic Ca2+ (increased) levels ALT, AST, MPO, TNFα, IL-1β (increased); γ-GT (decreased) | [168] |
Oxidative stress and inflammation | |||||
Cd free indium -based QDs | 4 nm (TEM) | Lister Hooded rats | 12.5 & 50 mg/kg b.w. (Iv) for 24 h. 1 wk, 4 wk | ALT, AST, ALP (slightly increased); No hepatic damage | [25] |
CdTe/CdS QDs | 12 nm (TEM) | HL-7702; HepG2 cells | 1- 32 nM for 48 h | Lysosomal internalization; Abnormal activation of lysosomal enzymes; ROS generation (increased); Autophagy | [3] |
Apoptosis independent nanotoxicity | |||||
CdTe QDs | 15.25 ± 0.34 nm (TEM) | BALB/c mice | 0.4, 2, 5, 6, 7, and 10 mg/kg b.w (Iv) for 24 h. 5 mg/kg b.w. (Iv)2 h, 24 h, 3 d (d), and 1 wk (w) | AST, ALT, T-bil (increased); Albumin (decreased); liver accumulation | [173] |
CdTe QDs | 15.25 ± 0.34 nm (TEM) | BALB/c mice | 0.4, 2, 5, 6, 7, and 10 mg/kg b.w (Iv) for 24 h. 5 mg/kg b.w. (Iv) 2 h, 24 h, 3 d (d), and 1 wk (w) | tGSH, ATP (depletion) GST, CAT (decreased) SOD activity (increased); Hmox I, Ncf-1, Ncf-2 (upregulated expression); PGC-1α (increased) | [9] |
Oxidative stress, apoptosis | |||||
CdTe QDs | 2.2-3.0 nm (TEM) | ICR mice; KUP5 cells | 2.5 & 10 μM/kg· b.w. (Iv) single dose once per wekk for 14 d; 5, 50 & 500 NM | IL-1β, TNF-α, IL-6 (increased); Assembly of NLRP3 inflammasome; ROS productin (increased); Activation of NF-KB pathway; Kupffer cell activation | [174] |
Oxidative stress, Inflammation |
- Citation: Das SK, Sen K, Ghosh B, Ghosh N, Sinha K, Sil PC. Molecular mechanism of nanomaterials induced liver injury: A review. World J Hepatol 2024; 16(4): 566-600
- URL: https://www.wjgnet.com/1948-5182/full/v16/i4/566.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i4.566